Developer docs
API playgroundTry for free, no card

Search company profiles

Azora Therapeutics

Full company profile

uuid0000no7

Namestring
Azora Therapeutics
Legal namestring
Azora Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Azora Therapeutics is a pre-clinical-stage biopharmaceutical company founded in 2017 and headquartered in California, developing novel therapeutics for serious inflammatory diseases. Its lead and only disclosed asset is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed as an oral treatment for ulcerative colitis. The compound's defining technical feature is a colon-targeted delivery mechanism designed to act locally in the affected colon tissue, addressing a chronic inflammatory bowel disease with significant unmet need. The company operated as a lean private entity with 1–10 employees under founders Matt Davidson (CEO) and Julie Saiki (COO), with no commercial revenue and no marketed products.

The company's business model is pre-commercial biotech R&D: it has historically funded operations through exempt private securities offerings rather than product sales, with approximately $7.73 million raised in 2021 and ~$581K in 2023 via SEC Form D filings. Customer-facing activity is limited to identifying the eventual patient population — ulcerative colitis sufferers — and defining a single horizontal use case. Proof-of-concept clinical testing is planned for 2027, with Phase 1 trials targeted for mid-2027, meaning the first regulatory and commercial inflection points are still forward-looking.

On June 11, 2026, Azora was acquired by Adial Pharmaceuticals for $32 million, with former Azora shareholders retaining approximately 51% of the combined company on a fully-diluted basis. A concurrent private placement of up to $64 million ($32M upfront plus $32M tied to Phase 1 initiation) was led by Coastlands Capital with Kern Capital, Boxer Capital, Stonepine Capital, and AuGC BioFund. Post-acquisition, AT177 will be advanced through Adial's clinical and commercial infrastructure, with revenue mechanics expected to follow a pharmaceutical product sales model contingent on regulatory approval.

Short descriptiontext

Azora Therapeutics is a pre-clinical biopharmaceutical company developing AT177, a proprietary colon-targeted aryl hydrocarbon receptor agonist for ulcerative colitis. Founded in 2017 in California, it was acquired by Adial Pharmaceuticals in June 2026 for $32 million.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inflammatory disease therapeutics, biopharmaceutical drug development, colon-targeted drug delivery, aryl hydrocarbon receptor agonist, ulcerative colitis treatment
Industry2 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inflammatory Bowel Disease Therapeutics
No data
Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Pre-commercial stage. The company was developing drug candidate AT177 for ulcerative colitis. Following acquisition by Adial Pharmaceuticals in 2026, the combined company will commercialize AT177 upon regulatory approval.

citybiz.co
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Azora Therapeutics is a pre-commercial biotechnology company developing AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist intended as an oral therapy for ulcerative colitis. The asset is the company's sole clinical-stage drug candidate and was acquired by Adial Pharmaceuticals in 2026 for advancement through clinical development toward commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Proof-of-concept clinical testing planned for 2027; Phase 1 clinical trials targeted for mid-2027
Product overview1 text field

Azora Therapeutics is a biotechnology company focused on developing novel therapeutics for inflammatory diseases. Their primary product is AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist. Following the acquisition by Adial Pharmaceuticals in 2026, AT177 is being advanced through clinical development for ulcerative colitis with proof-of-concept clinical testing planned for 2027.

Product and service1 record
1AT177
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-11
Description

Adial Pharmaceuticals acquired Azora Therapeutics for $32 million, bringing AT177, an oral treatment for ulcerative colitis, into its pipeline. The acquisition creates a combined company with Azora equity holders owning approximately 51% of the combined entity on a fully-diluted basis.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Owns etrasimod (via Arena acquisition) for UC and operates a broader inflammation/immunology franchise. Competes directly with AT177's commercial positioning.

TypeDirect peer
Description

Clinical-stage inflammation/immunology company that developed GB004, an investigational therapy for ulcerative colitis. Direct peer given similar stage and UC therapeutic focus; serves as a cautionary comparable given its mid-stage clinical setbacks.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing omilancor, an oral gut-restricted LANCL2 agonist for UC. Direct peer given shared focus on orally administered, locally-acting mechanisms for inflammatory bowel disease. Acquired by AbbVie in 2024.

4Morphic Therapeutic
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing oral integrin inhibitors for inflammatory bowel disease, including UC. Direct peer given small-molecule oral approach to UC. Acquired by Eli Lilly in 2024 for approximately $3.2B.

5Prometheus Biosciences
TypeDirect peer
Description

Clinical-stage biotechnology company developing PRA023 for UC and other immune-mediated diseases. Direct peer given late-stage UC focus with novel mechanism. Acquired by Merck in 2023 for approximately $10.8B, illustrating upside in this therapeutic area.

TypeDirect peer
Description

Developed etrasimod, an oral S1P receptor modulator approved for UC. Closely comparable given oral, targeted approach to UC inflammation; acquired by Pfizer in 2022 for approximately $6.7B.

TypeBroad incumbent
Description

Major incumbent in UC with HUMIRA (adalimumab), SKYRIZI (risankizumab), and RINVOQ (upadacitinib). Represents the dominant commercial and competitive reference point for any new UC entrant.

8Bristol Myers Squibb
TypeBroad incumbent
Description

Markets ZEPOSIA (ozanimod), an oral S1P receptor modulator approved for UC. Closest broad incumbent competitor in the oral UC therapy category.

TypeBroad incumbent
Description

Markets OMVOY (mirikizumab), an IL-23 antagonist approved for UC, and acquired Morphic Therapeutic. Major incumbent shaping the competitive landscape for new UC entrants.

TypeBroad incumbent
Description

Markets ENTYVIO (vedolizumab), a leading gut-selective biologic for UC. Represents an entrenched competitor with deep gastroenterology commercial infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Azora Therapeutics

Inflammatory Bowel Disease Therapeuticsazoratherapeutics.com

Azora Therapeutics is a pre-clinical biopharmaceutical company developing AT177, a proprietary colon-targeted aryl hydrocarbon receptor agonist for ulcerative colitis. Founded in 2017 in California, it was acquired by Adial Pharmaceuticals in June 2026 for $32 million.

What Azora Therapeutics does

Azora Therapeutics is a pre-clinical-stage biopharmaceutical company founded in 2017 and headquartered in California, developing novel therapeutics for serious inflammatory diseases. Its lead and only disclosed asset is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed as an oral treatment for ulcerative colitis. The compound's defining technical feature is a colon-targeted delivery mechanism designed to act locally in the affected colon tissue, addressing a chronic inflammatory bowel disease with significant unmet need. The company operated as a lean private entity with 1–10 employees under founders Matt Davidson (CEO) and Julie Saiki (COO), with no commercial revenue and no marketed products.

The company's business model is pre-commercial biotech R&D: it has historically funded operations through exempt private securities offerings rather than product sales, with approximately $7.73 million raised in 2021 and ~$581K in 2023 via SEC Form D filings. Customer-facing activity is limited to identifying the eventual patient population — ulcerative colitis sufferers — and defining a single horizontal use case. Proof-of-concept clinical testing is planned for 2027, with Phase 1 trials targeted for mid-2027, meaning the first regulatory and commercial inflection points are still forward-looking.

On June 11, 2026, Azora was acquired by Adial Pharmaceuticals for $32 million, with former Azora shareholders retaining approximately 51% of the combined company on a fully-diluted basis. A concurrent private placement of up to $64 million ($32M upfront plus $32M tied to Phase 1 initiation) was led by Coastlands Capital with Kern Capital, Boxer Capital, Stonepine Capital, and AuGC BioFund. Post-acquisition, AT177 will be advanced through Adial's clinical and commercial infrastructure, with revenue mechanics expected to follow a pharmaceutical product sales model contingent on regulatory approval.

Azora Therapeutics firmographics

Firmographics
Name
Azora Therapeutics
Legal name
Azora Therapeutics, Inc.
Website
https://azoratherapeutics.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
1–10 employees
Short description
Azora Therapeutics is a pre-clinical biopharmaceutical company developing AT177, a proprietary colon-targeted aryl hydrocarbon receptor agonist for ulcerative colitis. Founded in 2017 in California, it was acquired by Adial Pharmaceuticals in June 2026 for $32 million.
Ownership category
akta.pro rank

Azora Therapeutics industry classification

Industry
Product category
Inflammatory Bowel Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Inflammatory disease therapeutics
  • Biopharmaceutical drug development
  • Colon-targeted drug delivery
  • Aryl hydrocarbon receptor agonist
  • Ulcerative colitis treatment

Where Azora Therapeutics is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Azora Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical product sales: Pre-commercial stage. The company was developing drug candidate AT177 for ulcerative colitis. Following acquisition by Adial Pharmaceuticals in 2026, the combined company will commercialize AT177 upon regulatory approval.

Azora Therapeutics product offering

Product offering

Core offering

Azora Therapeutics is a pre-commercial biotechnology company developing AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist intended as an oral therapy for ulcerative colitis. The asset is the company's sole clinical-stage drug candidate and was acquired by Adial Pharmaceuticals in 2026 for advancement through clinical development toward commercialization.

Product overview

Azora Therapeutics is a biotechnology company focused on developing novel therapeutics for inflammatory diseases. Their primary product is AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist. Following the acquisition by Adial Pharmaceuticals in 2026, AT177 is being advanced through clinical development for ulcerative colitis with proof-of-concept clinical testing planned for 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • AT177

Quantifiable outcome

  • Proof-of-concept clinical testing planned for 2027; Phase 1 clinical trials targeted for mid-2027

Companies that use Azora Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Azora Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Azora Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Adial PharmaceuticalsflagshipStrategic or Co-development Partner · 11 June 2026Adial Pharmaceuticals acquired Azora Therapeutics for $32 million, bringing AT177, an oral treatment for ulcerative colitis, into its pipeline. The acquisition creates a combined company with Azora equity holders owning approximately 51% of the combined entity on a fully-diluted basis.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Azora Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Owns etrasimod (via Arena acquisition) for UC and operates a broader inflammation/immunology franchise. Competes directly with AT177's commercial positioning.
  • AbbVie: Major incumbent in UC with HUMIRA (adalimumab), SKYRIZI (risankizumab), and RINVOQ (upadacitinib). Represents the dominant commercial and competitive reference point for any new UC entrant.
  • Bristol Myers Squibb: Markets ZEPOSIA (ozanimod), an oral S1P receptor modulator approved for UC. Closest broad incumbent competitor in the oral UC therapy category.
  • Eli Lilly: Markets OMVOY (mirikizumab), an IL-23 antagonist approved for UC, and acquired Morphic Therapeutic. Major incumbent shaping the competitive landscape for new UC entrants.
  • Takeda Pharmaceutical: Markets ENTYVIO (vedolizumab), a leading gut-selective biologic for UC. Represents an entrenched competitor with deep gastroenterology commercial infrastructure.

Direct peers

  • Gossamer Bio: Clinical-stage inflammation/immunology company that developed GB004, an investigational therapy for ulcerative colitis. Direct peer given similar stage and UC therapeutic focus; serves as a cautionary comparable given its mid-stage clinical setbacks.
  • Landos Biopharma: Clinical-stage biopharmaceutical company developing omilancor, an oral gut-restricted LANCL2 agonist for UC. Direct peer given shared focus on orally administered, locally-acting mechanisms for inflammatory bowel disease. Acquired by AbbVie in 2024.
  • Morphic Therapeutic: Clinical-stage biopharmaceutical company developing oral integrin inhibitors for inflammatory bowel disease, including UC. Direct peer given small-molecule oral approach to UC. Acquired by Eli Lilly in 2024 for approximately $3.2B.
  • Prometheus Biosciences: Clinical-stage biotechnology company developing PRA023 for UC and other immune-mediated diseases. Direct peer given late-stage UC focus with novel mechanism. Acquired by Merck in 2023 for approximately $10.8B, illustrating upside in this therapeutic area.
  • Arena Pharmaceuticals: Developed etrasimod, an oral S1P receptor modulator approved for UC. Closely comparable given oral, targeted approach to UC inflammation; acquired by Pfizer in 2022 for approximately $6.7B.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Azora Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Azora Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Azora Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Azora Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Azora Therapeutics

What does Azora Therapeutics do?

Azora Therapeutics is a pre-commercial biotechnology company developing AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist intended as an oral therapy for ulcerative colitis. The asset is the company's sole clinical-stage drug candidate and was acquired by Adial Pharmaceuticals in 2026 for advancement through clinical development toward commercialization.

Is Azora Therapeutics a public or private company?

Azora Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Azora Therapeutics founded?

Azora Therapeutics was founded in 2018. It employs 1 to 10 people.

Where is Azora Therapeutics based?

Azora Therapeutics is headquartered in Los Angeles, United States, in the North America region.

How does Azora Therapeutics make money?

One revenue line is on record: pharmaceutical product sales.

Who are Azora Therapeutics's main competitors?

Broad incumbents on record are Pfizer, AbbVie, Bristol Myers Squibb, Eli Lilly and Takeda Pharmaceutical. Direct peers are Gossamer Bio, Landos Biopharma, Morphic Therapeutic, Prometheus Biosciences and Arena Pharmaceuticals.

Does Azora Therapeutics have an API?

No public API is recorded for Azora Therapeutics.

What industry is Azora Therapeutics in?

Azora Therapeutics's product category is Inflammatory Bowel Disease Therapeutics. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialAzora Therapeutics Appoints Board Of Directors With Extensive Drug Development And Inflammatory Bowel Disease ExpertiseAzora Therapeutics appointed a board of directors with drug development and inflammatory bowel disease expertise. The company's lead program, AT177, is an oral aryl hydrocarbon receptor agonist for ulcerative colitis, with a Phase 1 trial planned for the first half of 2027.TradingViewJones Trading initiates coverage of Azora Therapeutics at Buy, sets price target at $14Jones Trading initiated coverage of Azora Therapeutics at Buy with a price target of $14. The target implies an upside of 267.5% from the Oct 30 close of $3.81.Investing.comJones Trading initiates Azora Therapeutics stock with buy ratingJones Trading initiated coverage on Azora Therapeutics with a Buy rating and a $14 price target, while the stock trades at $3.81. The company, formed via a reverse merger with Adial Pharmaceuticals, is developing AT177 for inflammatory bowel disease, with 28.5 million proforma shares outstanding.Investing.comTD Cowen initiates Azora Therapeutics stock with buy ratingTD Cowen initiated coverage on Azora Therapeutics with a Buy rating, citing its lead drug AT177 for inflammatory bowel disease. The stock rose 146% over six months to $3.81, though down 31% year-to-date. The company plans a Phase I trial in the first half of 2027.MarketWatchAdial Rebrands as Azora Therapeutics, Changes Leadership After AcquisitionAdial Pharmaceuticals rebranded as Azora Therapeutics and will trade on Nasdaq under AZR. New leadership includes co-founders Matt Davidson and Julie Saiki as CEO and CSO, with plans to focus on lead candidate AT177 for ulcerative colitis. A Phase 1 trial is expected to launch in the first half.Stock TitanAdial renamed Azora Therapeutics; Phase 1 expected in 2027Adial Pharmaceuticals changed its name to Azora Therapeutics, with stock trading under ticker AZR on Nasdaq starting Oct 29, 2026. The company's lead asset AT177, an oral colon-targeted AhR agonist for ulcerative colitis, is expected to enter Phase 1 clinical trials in the first half of 2027.Business & FinancialAdial Pharmaceuticals Announces Name Change To Azora Therapeutics And New Executive Team, Focused On Advancing AT177, An Oral, Colon-Targeted Ahr Agonist For Ulcerative ColitisAdial Pharmaceuticals changed its name to Azora Therapeutics, with stock trading on Nasdaq under ticker AZR on October 29, 2026. The company's lead asset, AT177, an oral colon-targeted AhR agonist for ulcerative colitis, is expected to enter Phase 1 clinical trials in the first half of 2027. The company raised approximately $32 million in private placement financing.BioSpaceAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - September 30, 2026Adial Pharmaceuticals granted a new employee stock option to purchase 155,446 shares at $4.22 per share, with a ten-year term and four-year vesting. The award was made outside equity incentive plans under Nasdaq Listing Rule 5635(c)(4). The company's lead program AT177 is in IND-enabling studies, with an IND filing planned for the first half of 2027.BioSpaceAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - August 25, 2026Adial Pharmaceuticals granted a new employee stock option to purchase 307,814 shares at $5.76 per share, with a ten-year term and four-year vesting. The award was made outside equity incentive plans under Nasdaq Listing Rule 5635(c)(4). The company's lead program AT177 is in IND-enabling studies, with an IND filing planned for the first half of 2027.GlobeNewswireAdial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business UpdateAdial Pharmaceuticals reported Q2 2026 results with a $52 million net loss and $28.7 million in cash, and closed a $32 million financing tranche. The company acquired Azora Therapeutics, adding AT177 for ulcerative colitis, and plans an IND filing in the first half of 2027.